The Expression Profiling of Serum miR-92a, miR-134 and miR-375 in Acute Ischemic Stroke

Figures & data

Table 1. Demographics description and routine biochemical findings.

n	25	70	–
Age (range, years)	49–62	42–79	0.2328
Mean ± SD, years	57.3 ± 3.27	59.4 ± 8.36
RBG (range, mg/dl)	85.0–128	105–398	<0.0001 ^†
Mean ± SD, mg/dl	103 ± 13.1	218 ± 98
T.Ch (range, mg/dl)	134–202	137–259	0.0020 ^†
Mean ± SD, mg/dl)	180 ± 18.4	196 ± 26.7
TG (range, mg/dl)	125–168	52–219	0.1162
Mean ± SD, mg/dl	147 ± 15.5	132 ± 37.5
LDL-ch (range, mg/dl)	78.0–142	72–178	0.0047 ^†
Mean ± SD, mg/dl	108 ± 5.16	122 ± 23.7
HDL-ch (range, mg/dl)	30.0–76.0	35–62	0.0411 ^†
Mean ± SD, mg/dl	50.8 ± 12.8	47 ± 6.73
VLDL-ch (range, mg/dl)	19.2–42.0	10.4–43.8	<0.0001 ^†
Mean ± SD, mg/dl	32.2 ± 6.84	26.5 ± 7.49
Cr. (range, mg/dl)	0.860–1.21	0.88–1.50	<0.0001 ^†
Mean ± SD, mg/dl	1.00 ± 0.113	1.17 ± 0.135
Urea (range, mg/dl)	18.0–43.6	24–51	0.0071 ^†
Mean ± SD, mg/dl	32.2 ± 8.16	37 ± 7.18

† Significant from control subjects at p < 0.05.

AIS: Acute ischemic stroke; Cr: Creatinine; HDL: High density lipoprotein; LDL: Low density lipoprotein; RBG: Random blood glucose; SD: Standard deviation; T.ch: Total cholesterol; TG: Triglyceride; VLDL: Very low density lipoprotein.

Figure 1. The expression pattern of the studied miRNAs in acute ischemic stroke patients.

Table 2. The expression pattern of serum-selected miRNAs in different groups.

MiRNAs	General (AIS) (n = 70)	DM (n = 15)	HTN (n = 25)	DM + HTN (n = 21)	Non DM + Non HTN (n = 9)
MiR-92a   Mean ± SD   Median (IQR)   Range   p	-1.86 ± 1.36 -2.62 to -0.934 -5.39 to 0.850 <0.0001 ^†	-1.59 ± 1.09 -2.10 to -0.884 -3.80 to -0.032 0.0028 ^†	-1.57 ± 1.30 -2.09 to -0.896 -4.85 to 0.850 0.0001 ^†	-2.07 ± 1.50 -3.60 to -0.710 -4.20 to 0.191 <0.0001 ^†	-2.79 ± 1.31 -3.31 to -1.88 -5.39 to -1.84 <0.0001 ^†
MiR-134   Mean ± SD   Median (IQR)   Range   p	0.853 ± 1.34 0.284 to 1.72 -3.13 to 2.98 <0.0001 ^†	0.355 ± 1.11 -1.77 to 1.73 -0.671 to 1.04 0.9142	0.781 ± 1.54 -0.059 to 1.79 -3.13 to 2.63 0.1437	1.11 ± 1.60 0.659 to 1.70 -1.15 to 2.98 0.0212 ^†	1.27 ± 1.67 0.144 to 2.48 -1.84 to 2.54 0.1234
MiR-375   Mean ± SD   Median (IQR)   Range   p	-1.63 ± 1.38 -2.20 to -1.12 -5.64 to 2.74 <0.0001 ^†	-2.00 ± 1.82 -5.64 to 1.46 -3.02 to -0.995 0.0002 ^†	-1.51 ± 1.73 -2.42 to -0.606 -5.57 to 2.74 0.0002 ^†	-1.60 ± 0.638 -2.14 to -1.31 -2.80 to -0.161 0.0005 ^†	-1.47 ± 0.492 -1.94 to -1.08 -2.19 to -0.808 0.0693

† Significant from control subjects at p < 0.05.

AIS: Acute ischemic stroke; DM: Diabetes mellitus; HTN: Hypertension; IQR: interquartile range; miRNA: MicroRNA; SD: Standard deviation.

Figure 2. The expression pattern of the studied miRNAs among acute ischemic stroke groups.

DM: Diabetes mellitus; HTN: Hypertension.

Figure 3. Receiver operator characteristic curve of the studied miRNAs.

ROS: Receiver operator characteristic.

Table 3. The diagnostic accuracy of the targeted miRNAs in AIS patients from the control subjects.

MiRNAs	Cutoff	AUC	Sn%	Sp%	95% CI	p-value
MiR-92a	<-0.821	0.9183	81%	92.0%	0.861–0.970	<0.0001
MiR-134	>0.4869	0.764	72.4%	88.0%	0.658–0.869	0.0001
MiR-375	<-0.8185	0.898	81.0%	96.0%	0.827–0.969	<0.0001

Table 4. Pearson correlation coefficient between the studied miRNAs and patients' characteristics.

Parameters	miR-92a		miR-134		miR-375
	r	p-value	r	p-value	r	p-value
Age	0.0195	0.8844	0.180	0.1760	0.0812	0.5447
Rbs	-0.0499	0.7101	-0.0821	0.5399	-0.143	0.2859
T.ch	-0.0125	0.9259	0.137	0.3055	0.169	0.2054
Tg	-0.0508	0.7052	0.136	0.3093	0.0864	0.5190
LDL-ch	0.0301	0.8224	0.0949	0.4786	0.122	0.3631
HDL-ch	-0.113	0.3997	0.101	0.4501	0.128	0.3387
VLDL-ch	-0.0508	0.7052	0.136	0.3093	0.0864	0.5190
Cr	-0.200	0.1327	0.0912	0.4960	0.0279	0.8354
Urea	-0.228	0.0847	0.0753	0.5745	-0.204	0.1251
miR-92a	1	–	-0.585	<0.0001 ^†	-0.228	0.0699
miR-134	-0.585	<0.0001 ^†	1	–	0.111	0.3821
miR-375	-0.228	0.0699	0.111	0.3821	1	–

† Significant linear correlation at p < 0.05 (two-tailed).

Cr: Creatinine; HDL: High density lipoprotein; LDL: Low density lipoprotein; RBG: Random blood glucose; T.ch: Total cholesterol; TG: Triglyceride; VLDL: Very low density lipoprotein.